Abstract on DGN Stimulation for Bladder and Bowel Disorders to be Presented at IUGA 2023 Conference15. June 2023
InnoCon Medical will participate in the ICS 2023 Toronto7. September 2023
We are happy to announce that Tom Bombeck has accepted an expanded role with InnoCon Medical ApS that includes responsibility for North American Marketing and Business Development. With his extensive market knowledge and experience in neuromodulation for the treatment of pelvic floor disorders, Tom will help prepare InnoCon for entering the U.S. and Canadian markets. The UCon System being developed by InnoCon is currently undergoing multiple European clinical investigations for the treatment of overactive bladder (OAB) and faecal incontinence (FI). Dorsal genital nerve stimulation (DGNS) with UCon may offer several advantages over other therapies, either existing or under development, for treating OAB and FI. While DGNS has been investigated in a handful of animal and human studies over the past twenty years, no company has developed a DGNS system for clinical use. The proprietary electrode designs incorporated into the UCon System have finally made clinical DGNS feasible. We are excited to have Tom on board in his expanded role to help us bring our UCon System to the U.S. and Canada.